DXCOVER


Dxcover is a pioneering company in early cancer detection, utilizing a multi-omic platform powered by light and machine learning. Their mission is to deploy innovative liquid biopsy technologies to enable earlier diagnosis of cancers, thereby improving survival rates and quality of life. With a focus on multiple cancers, Dxcover aims to transform cancer care through advanced spectroscopic analysis and artificial intelligence, making cancer detection faster, more accurate, and accessible globally.

Industries

biotechnology
health-care
health-diagnostics
machine-learning
medical

Nr. of Employees

small (1-50)


Patents

Sample container with integrated internal reflection element

US-12083519-B2

View Details

Infra-red spectroscopy system

US-11668646-B2

View Details

Infra-red spectroscopy system

US-11215553-B2

View Details

Methods of diagnosing proliferative disorders

US-10288615-B2

View Details

Products

Multi-omic spectroscopic liquid biopsy platform

An integrated slide-based infrared spectroscopy platform combining automated sample handling and machine learning algorithms to detect disease-specific multi-omic signatures from microlitre-scale blood samples with rapid turnaround.

Clinical-stage spectroscopic diagnostic tests (disease-specific assays)

Indication-specific diagnostic assays under clinical evaluation for early detection and triage (examples include brain, colorectal, pancreatic and ovarian cancer applications).


Services

Collaborative engagements with clinical, pharmaceutical and diagnostic organisations to support clinical projects, co-development and commercialisation of spectroscopic diagnostic applications.

Design, execution and data generation for prospective and multi-centre clinical studies to evaluate diagnostic performance across multiple cancer indications.

Provision of sample requirements guidance and analytical services for discovery projects using infrared spectral analysis of biofluids.

Expertise Areas

  • Liquid biopsy development using vibrational (infrared) spectroscopy
  • Clinical trial design and multi-centre diagnostic validation
  • Machine learning for spectral diagnostics
  • Regulatory compliance and quality management for diagnostics (ISO 13485, CE pathway)
  • Show More (4)

Key Technologies

  • Attenuated Total Reflection Fourier-transform Infrared Spectroscopy (ATR-FTIR)
  • Multi-omic spectral analysis (proteome/lipidome/metabolome signatures)
  • Recurrent neural networks and ensemble machine learning for spectral data
  • Generative data augmentation for spectral datasets (GANs)
  • Show More (3)

News & Updates

Date: 24 June 2025 Opens U.S. headquarters in Nashville – a leading healthcare and life sciences hub Building the foundation…

GLASGOW, Scotland (April 30, 2025) Dxcover Limited, a clinical-stage diagnostics company pioneering its multiomic spectral analysis (MOSA-Dx™) for early detection…

February 03, 2025 09:00 AM GMT New capital raise from existing investors, as well as new investors, Macmillan Cancer Support…

Luke Pike MD, DPhil, Radiation Oncologist, joins Dxcover Scientific Advisory Board to advise the company on brain cancer diagnostic early…

Distinguished Abstract Award to be presented Wednesday July 31 at Academy of Diagnostics & Laboratory Medicine Annual Meeting in Chicago.…

We are thrilled to announce that Abigail Lishman has joined our team as the Head of Commercial Development in the…

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.